Diskusjon Triggere Porteføljer Aksjonærlister

BergenBio Fundamentale Forhold (BGBIO)

Biotek
#3910

BerGenBio ASA: Primary Insider notification

18 Likes
#3911

Legend!

4 Likes
#3912

Trond trår til igjen!
Ser ut til å kunne bli en kamp mellom Trond og gutta i kortbukser dette :laughing:!

2 Likes
#3913

Det er ikke umulig at Bemcentinib blir den beste løsningen på denne pandemien. I hvert fall hindre en masse dødsfall. Har veldig liten tro på at vaksinene vil gi særlig lang immunitet når ikke sykdommen selv gjør det.
Skulle tro at man får nok av pasienter til å være med på Accord testene i UK. De neste to månedene blir veldig spennende.

1 Like
#3914

Innleggelser i UK forsetter akselerasjonen.

Sist kjente døgn (26 oktober) ble det lagt inn 1489.
Det er ca 15x mer enn for to mnd siden.

Screenshot_20201030-181114_Chrome
Screenshot_20201030-181114_Chrome950×887 105 KB

Myndighetene i UK skal ha kred for at de var raskt med å få igang Accord da de så hva som var i ferd med å skje.

7 Likes
#3915

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre :slight_smile:

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

  1. @Multiple (245 likes)
  1. @eiken (163 likes)
  1. @Fornybar (154 likes)

Resten av topp 10:

  1. @drdr (146 likes)

  2. @alfred_e_neuman (124 likes)

  3. @Shattering84 (107 likes)

  4. @Flottesen (105 likes)

  5. @Mykle (104 likes)

  6. @Scrivener (96 likes)

  7. @HeldigFyr (94 likes)

Gratulerer!

#3917

BERGENBIO ASA: INVITATION TO THIRD QUARTER 2020 RESULTS

#3918

https://ashpublications.org/blood/issue/13

Ash abstracts er ute en dag for tidlig

10 Likes
#3919

Jeg får ikke opp abstractene, bare forsiden på tidsskriftet hvor de publiseres. Får du de opp?

#3920

Takk til @Boykie for disse. Her kommer det noen meldinger i morgen, I guess. (har ikke lest enda)

1 Like
#3921

ScreenHunter 692
ScreenHunter 692786×710 30.6 KB

4 Likes
#3922

Trodde abstraktene skulle komme først i midten av november. Bah.

#3923

Dette var vel en feil, kommer inne inn på abstraktene lenger.

#3924

Se tråden Biotekaksjer og en alternativ link av Boykie.

#3925

Fire treff på Bemcentinib:

2 Likes
#3926

bull

#3927

Efficacy and Safety of Bemcentinib in Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Failing Hypomethylating Agents

Results:

Between 2018 and 2020, 58 patients in 10 European centers were screened (MDS=27/AML=31) with a median age of 78 years (range, 62-86 years). 45 patients (MDS=21, AML=24) received at least one cycle of BEM and were eligible for safety and efficacy analysis after the first 4 months of treatment. Thirty six (80%) out of 45 patients were considered relapsed after a response to HMA, 8 (18%) had primary resistance and 1 patient (2%) had HMA intolerance. The median number of prior AZA or DAC cycles was 13. In addition, 18 patients (40%) (MDS=9/AML=9) were red blood cell transfusion-dependent.

Treatment with BEM was generally well tolerated with only low rates of grade 3-4 hematologic toxicities (n=7). Forty-seven serious adverse events (SAE) occurred in 22 patients (MDS=9/AML=13), mostly due to infectious complications (n=12), hematological toxicity (n=4) or gastrointestinal disturbance (n=6). Until the first 4 months of BEM treatment, the median number of BEM treatment cycles received was 1.5 (range, 0.5-4). During study, 9 patients (20%) died due to infection (MDS=1/AML=3), deterioration of general condition (MDS=1/AML=2) and progressive disease (MDS=0/AML=2). BEM treatment is currently ongoing in four patients (MDS=3/AML=1).

The primary endpoint was met in 9 of 45 patients (20.0%). Within the MDS cohort 33.3% achieved a response (n=7/21; CR=1, CRi= 3, SD=3), while 8.3% of patients (n=2/24) with AML achieved stable disease(SD). The 4 MDS patients achieving CR/CRi had a normal karyotype and a median baseline IPSS-R score of 4 (range 3-5). Among the MDS non-responders 4 patients had a complex karyotype, median IPSS-R score was 5 (range 3-5). Median baseline bone marrow blast count was 15% vs. 13% and median pretreatment hemoglobin-, platelet- and WBC levels were 9.2 g/dl (range 7.9-11.8 g/dl), 51 G/L(range 26-120 G/L) and 1.9x109/l (range 1.18-8.9 x109/l) vs. 9.6 g/dl (range 7.9-11.3 g/dl), 35 G/L (range 0-167 G/L) and 1.45x109/l (range 0.82-6.97 x109/l) comparing MDS responders (CR/CRi) vs MDS non-responders, respectively.

Preliminary data evaluating soluble AXL (sAXL) in blood plasma at baseline showed that 66.6 % (n=2/3) of MDS patients achieving CR/CRi displayed sAXL levels below a defined threshold, while this was only seen in 20% (n=2/10) of MDS non-responders.

Conclusion:

These results of the prospective phase II BERGAMO trial confirm, that single agent BEM is generally safe and well tolerated in this patient population with an unmet medical need. Importantly, BEM showed clinical efficacy in a subgroup of MDS patients. These encouraging clinical results are being further explored by an in depth translational research program aiming to identify additional molecular and biological prognostic factors associated with response

23 Likes
#3928

Ble trangt inn døra på slutten her :sunglasses:

1 Like
#3929

Oral presentation her også! Sweet.

4 Likes
#3930

Vil du dele tankene dine eller evt @Boykie vedr resultatet som foreligger her?

På forhånd takk

2 Likes